As medical technology continues to evolve and offer the latest solutions and treatment to patients, Samsung Electronics in Switzerland has been helping this progress by developing its products.
Samsung collaborated with Bottneuro AG, a Swiss medical technology startup dedicated to improving the diagnosis and treatment of Alzheimer’s disease, bringing an innovative and improved diagnosis and treatment solution to patients. Bottneuro AG chose the Samsung Galaxy Tab S8+ 5G1 Enterprise Edition2 to store and record treatment data in the Bottneuro solution.
Powerful treatment through innovative technologies
Bottneuro AG’s technology identifies areas of the brain affected by the disease using 3D magnetic resonance imaging and positron emission tomography. Once identified, these regions can be targeted and electronically stimulated with Miamind® neurostimulator technology. The Galaxy Tab S8+ 5G Enterprise Edition simplifies handling Bottneuro’s solution through a graphical interface.
Patients suffering from dementia often experience reduced cognitive function in the early stages of the disease, making it imperative for Bottneuro AG to find a device that is easy to operate and understand. With its intuitive interface and practicality, the Galaxy Tab S8+ 5G represents the ideal equipment for Bottneuro’s solution.
“We were looking for a simple and reliable solution for our app. We found this in the Galaxy Tab S8+ 5G Enterprise Edition and Samsung is giving us great support in the development,” said Julius Klaas, CTO of Bottneuro AG.
Seamless solutions in a single Galaxy tablet
The Galaxy Tab S8+ 5G Enterprise Edition offers a plethora of features and capabilities. It comes with a high-resolution Super AMOLED display, which offers brilliant clarity for patients and healthcare professionals, as well as long battery life.
The Miamind® neurostimulator is also powered directly by the Galaxy Tab S8+ 5G Enterprise Edition, and when the treatment is complete, the tablet automatically transmits the diagnostic and treatment information contained in the Bottneuro solution to Bottneuro AG via 5G data connectivity, allowing patients are comfortable in their own home. Additionally, the Galaxy Tab S8+ 5G Enterprise Edition is individually configurable via Samsung Knox, keeping confidential data and medical records private and protected.
Partnerships for the future
Breakthrough innovations like these wouldn’t be possible without partnerships, and Samsung has been proud to support and work with Bottneuro AG since the company’s founding in 2021.
“We are pleased to offer Bottneuro AG a reliable, secure and simple solution with Samsung Knox and support their new approach to care,” added Daniele Casella, Head of Mobile Experience B2B at Samsung Switzerland.
The effectiveness of Bottneuro AG’s new therapeutic treatment will be tested in several clinical studies this year. While the treatment is not yet commercially available, Bottneuro AG and Samsung remain optimistic about the progress that can be made to treat Alzheimer’s disease.
For more information about Bottneuro AG and the Samsung partnership, visit the Samsung Newsroom Switzerland, www.bottneuro.com or www.miamind.com.